Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients

NCT00904839 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00904839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00904839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of BIBF 1120 and FOLFOX Compared to Bevacizumab and FOLFOX in First Line Metastatic Colorectal Cancer Patients
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
January 31, 2012
Enrollment
128 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms